Cumberland Pharmaceuticals Inc. (CPIX)

1,7600 +0,1250 (+7,65%) Alla chiusura: 04:00PM EDT

Cumberland Pharmaceuticals Inc.

1600 West End Avenue
Suite 1300
Nashville, TN 37203
United States
615 255 0068
https://www.cumberlandpharma.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 91

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. A. J. Kazimi MBA	Founder, Chairman, President & CEO	952,53k	N/D	1958
Mr. John Michael Hamm	VP & CFO	258,38k	N/D	1956
Mr. James Lowrance Herman	Executive VP of National Accounts & Chief Compliance Officer	372,27k	N/D	1955
Mr. Chris T. Bitterman	Vice President of Sales & Marketing	290,87k	N/D	1965
Mr. Todd M. Anthony	Vice President of Organizational Development	304,94k	N/D	1961
Ms. Jean W. Marstiller	Senior VP of Administrative Services & Corporate Secretary	282,17k	38,53k	1950
Mr. Adam S. Mostafa	Managing Director	N/D	N/D	1980
Ms. Erin Smith Gull	Senior Corporate Relations Associate	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Governance aziendale

L'ISS Governance QualityScore di Cumberland Pharmaceuticals Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.